R&D channel feed – Endpoints News

R&D channel feed

Genentech slashes nearly 500 jobs in strategic shift to 'local healthcare ecosystems.' Clinical specialists make up the biggest group

5 years ago

GSK’s latest pipeline review includes a slate of COPD programs headed to the scrap heap

5 years ago

Sanofi prunes its pipeline, taking the ax to a lineup of drug, vaccine programs

5 years ago

Test results in hand, Thrive raises $257M to push liquid biopsy toward approval

5 years ago

Roche declares a PhIII failure for Covid-19 as the IL-6 repurposing theory bites the dust

5 years ago

Amgen dumps early-stage CD38xCD3 bispecific as 3 programs are sidelined by trial setbacks

5 years ago

After stopping Farxiga trial early, AstraZeneca declares success in CKD treatment

5 years ago

A protein engineering platform spawns a new IL-2 player out of Basel, with human trials looming next summer

5 years ago

Humanigen momentum barges on as Covid-19 candidate is selected for NIAID trial

5 years ago

Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb

5 years ago

TCR² releases early data from some PhI patients, sparking optimism from analysts

5 years ago

UCB touts another psoriasis win, this time over Cosentyx, as they look to break into packed market

5 years ago

Ruxolitinib passes another PhIII test for graft-versus-host disease, a win for Incyte and Novartis

5 years ago

AMAG signs European partner as they hunt cash to get their lead drug through the clinic

5 years ago

FDA lifts hold on CymaBay’s NASH drug, but the company may still leave the ailing field

5 years ago

Genfit throws in the towel on NASH, exiting a tumultuous field full of bright market prospects and lethal R&D setbacks

5 years ago

Seer raises another $55M and finally reveals proteomic tech — can it hold up?

5 years ago

Novartis quietly buries another failed eczema drug, with a $485M hit embedded in the footnotes

5 years ago

Acadia’s shot at beating a ‘fickle’ major depression challenge misses the mark in a failed PhIII

5 years ago

Not just AstraZeneca — CanSino Biologics also unveils Phase II data, showing antibody and T cell response

5 years ago

AstraZeneca, Oxford researchers champion a one-two punch against Covid-19 in first human study

5 years ago

Amplyx touts upbeat readout from a small PhII study for lead antifungal

5 years ago

Small AI biotech BioXcel surges on positive PhIII results, setting up dementia and Alzheimer’s test

5 years ago

Ex-Sanofi Genzyme chief David Meeker hops to a new biotech CEO post, this time focusing on quick leap to commercialization

5 years ago

First page Previous page 194 195 196197198 199 200 Next page Last page